
Specialises in cephalosporins, manufacturing APIs and formulations with capabilities in sterile injectables. Operates EHGC and is engaged in menthol business.
Approved slump sales of API/formulations business and menthol assets aiming for debt freedom; delisted GDRs in 2024.
Derabassi (Punjab), Bhatoli Kalan (Himachal Pradesh), Bari Brahmana (Jammu), formulation unit and EHGC unit across India.